Postmenopause Symptoms: Labs, Diagnosis, and Next Steps

Why Postmenopausal Symptoms Happen

The ovaries produce progressively less estradiol and progesterone after menopause, and this decline drives most postmenopausal symptoms. Estrogen receptors exist in the brain, bones, heart, bladder, vaginal mucosa, and skin, which is part of why low estrogen affects several organ systems at once [1].

The Hormonal Cascade

During the menopausal transition, the hypothalamic-pituitary-ovarian axis shifts permanently. The pituitary gland increases follicle-stimulating hormone (FSH) output in an attempt to stimulate ovarian follicles that no longer respond, and FSH levels rise and stay elevated. Estradiol, the most potent circulating estrogen, drops below 20 pg/mL in most postmenopausal women [2].

This is not a single event. The hormonal environment continues to change for years after the final period. Adrenal androgens (DHEA-S, androstenedione) also decline with age and are thought to contribute to fatigue, reduced libido, and changes in body composition, though the evidence connecting specific androgen levels to specific symptoms is less settled than for estrogen [3].

Vasomotor Symptoms and the Brain

Hot flashes and night sweats originate in the thermoregulatory center of the hypothalamus. Estrogen withdrawal is thought to narrow the thermoneutral zone, the temperature range the body tolerates before triggering a cooling response. The Study of Women's Health Across the Nation (SWAN, N=3,302) found that vasomotor symptoms lasted a median of 7.4 years, and women who began having hot flashes before their final period experienced them for over 11 years on average [4].

Bone, Heart, and Metabolic Effects

Estrogen is a direct inhibitor of osteoclast activity. Without it, bone resorption outpaces formation. Clinical guidance generally describes accelerated bone loss in the first 5 to 7 years after menopause, with some women losing a substantial share of bone density in that window. Cardiovascular risk also shifts after menopause: lipid profiles tend to worsen and arterial stiffness increases. Postmenopausal women show a higher rate of cardiovascular disease than premenopausal women of similar age, a pattern first documented in the Framingham cohort and confirmed in later studies, though the exact magnitude of the increase varies across studies and should not be reduced to a single number [6].

The Postmenopause Lab Panel: What to Order and Why

A focused set of laboratory tests confirms postmenopausal status, identifies treatable conditions that mimic menopause, and screens for the long-term complications of estrogen deficiency. Not every woman needs every test, but a baseline panel within the first 1 to 2 years of suspected postmenopause is reasonable practice consistent with North American Menopause Society (NAMS) guidance [7].

Hormone Levels

FSH (follicle-stimulating hormone): A single FSH value above 30 mIU/mL, drawn in a woman who has not menstruated for 12 months, is consistent with postmenopausal status. FSH testing is most useful in women aged 40 to 45 with ambiguous symptoms, or in women who have had a hysterectomy without oophorectomy and cannot use bleeding patterns to date menopause [8].

Estradiol: Levels below 20 pg/mL are consistent with postmenopause. This value also serves as a baseline before initiating hormone therapy and can help guide dose adjustments during treatment.

TSH (thyroid-stimulating hormone): Hypothyroidism becomes more common with age and produces symptoms (fatigue, weight gain, cold intolerance, cognitive fog) that overlap heavily with postmenopause, which is why clinical guidelines for hypothyroidism management recommend screening older adults [9]. Ask your clinician what screening interval fits your history rather than assuming a fixed schedule applies to you.

Metabolic and Cardiovascular Panel

Lipid panel (total cholesterol, LDL, HDL, triglycerides): ACC/AHA cardiovascular prevention guidance identifies early or premature menopause (before roughly age 40 to 45) specifically, not menopause at a typical age, as a risk-enhancing factor for atherosclerotic cardiovascular disease. Regardless of the age at which it occurred, a baseline lipid panel with periodic repeat testing is a reasonable part of postmenopausal care [10].

Fasting glucose and HbA1c: Insulin resistance tends to rise after menopause, which is one reason glucose screening is worth doing in this population. When prediabetes is caught, randomized trial evidence from the Diabetes Prevention Program showed that intensive lifestyle intervention reduced progression to type 2 diabetes by 58 percent compared with placebo, and metformin reduced it by 31 percent, though that trial was not restricted to postmenopausal women [11].

Complete metabolic panel (CMP): Assesses kidney and liver function before starting any new medication, including HRT. Calcium levels on a CMP also provide a rough screen for hyperparathyroidism, which becomes more common with age.

Bone Density Assessment

DEXA scan: The U.S. Preventive Services Task Force (USPSTF) recommends bone density screening via dual-energy X-ray absorptiometry (DEXA) for all women aged 65 and older, and for younger postmenopausal women whose 10-year fracture risk (calculated by FRAX) equals or exceeds that of a 65-year-old woman with no additional risk factors [12]. A T-score of -1.0 to -2.5 indicates osteopenia. A T-score below -2.5 indicates osteoporosis.

Optional but Clinically Useful Tests

Vitamin D (25-hydroxyvitamin D): Insufficiency is common in the general population and appears to be more common in postmenopausal women, though exact prevalence estimates vary by region, season, and assay method. The Endocrine Society recommends maintaining levels of 30 to 50 ng/mL for bone health [13].

DHEA-S: Low levels may correlate with fatigue, low libido, and reduced well-being, though DHEA supplementation for these symptoms remains controversial and is not something to start without medical guidance.

Vaginal pH: A simple office test. Postmenopausal vaginal pH tends to rise above 5.0 (premenopausal range is roughly 3.5 to 4.5), which is consistent with estrogen deficiency at the tissue level.

A Decision Framework: What Should You Actually Do Next?

Lab values alone do not tell you what to do. The next step depends on three questions, in this order.

1. Is anything happening that needs care now, not eventually? Answer yes to any of the following and the next step is a call or visit to your clinician, not a wait-and-see approach:

• Any vaginal bleeding after 12 months without a period
• New chest pain, exertional shortness of breath, or palpitations
• A repeat DEXA showing more than 3 to 5 percent bone loss in a year
• Mood changes that include thoughts of self-harm

If none apply, move to question 2.

2. Are you a reasonable candidate for systemic hormone therapy? This mainly turns on two facts: your age and how long it has been since your final period.

• Under 60 and within 10 years of menopause onset, with no contraindication (history of breast cancer, unprovoked VTE, active liver disease, undiagnosed vaginal bleeding): systemic HRT is a reasonable first-line option to discuss for moderate-to-severe hot flashes, night sweats, or GSM, per NAMS guidance [7].
• Over 60, more than 10 years past menopause onset, or a contraindication is present: the risk-benefit balance shifts. Non-hormonal options (fezolinetant, SSRIs/SNRIs, gabapentin for vasomotor symptoms; low-dose vaginal estrogen, ospemifene, or prasterone for GSM specifically, since local vaginal estrogen carries a different risk profile than systemic therapy) are the more common starting point. This is a conversation for your prescriber, not a self-directed choice.
• Symptoms are mild and tolerable: lifestyle measures (layered clothing, cooling strategies, avoiding known triggers, vaginal moisturizers for dryness) may be enough before adding medication.

3. What is the minimum monitoring you need regardless of treatment choice? Every postmenopausal woman, treated or not, benefits from: a lipid panel and fasting glucose or HbA1c on a periodic basis, a DEXA scan per the USPSTF schedule above, and an annual visit that checks blood pressure and screens for the red flags in question 1. Women on HRT add an earlier follow-up, typically around 3 months after starting, to assess symptom response and side effects, plus annual reassessment of whether continued treatment still makes sense.

The exceptions that change this framework: a personal or strong family history of breast or endometrial cancer, a clotting disorder, migraine with aura (which affects estrogen formulation choices), or a hysterectomy (which changes whether a progestogen is needed). None of these are addressed adequately by a general article. Bring them to the visit.

Recognizing the Full Symptom Spectrum

Postmenopause is not just hot flashes. The symptom profile spans multiple organ systems, and many women do not connect their complaints to estrogen loss.

Vasomotor and Sleep Symptoms

Hot flashes affect a large share of postmenopausal women, with estimates commonly ranging from 50 to 80 percent. Night sweats disrupt sleep architecture. A study in Menopause examining sleep and vasomotor symptoms in postmenopausal women found that frequent night sweats were associated with a meaningfully higher rate of clinical insomnia compared with women without vasomotor symptoms [14].

Genitourinary Syndrome of Menopause (GSM)

GSM, formerly called vulvovaginal atrophy, is common, with survey-based estimates reaching as high as 84 percent of postmenopausal women [15]. Symptoms include vaginal dryness, burning, irritation, pain with intercourse, and recurrent urinary tract infections. Unlike hot flashes, GSM tends not to improve on its own over time and can worsen progressively without treatment.

Cognitive and Mood Changes

Estrogen modulates serotonin, norepinephrine, and acetylcholine activity. The KEEPS-Continuation cognitive and affective study reported that women who received estrogen therapy within roughly 6 years of menopause showed less decline in verbal memory compared with placebo, though the study's authors were careful to note this does not establish that estrogen prevents dementia [16]. Depression risk also appears to rise during the menopausal transition and early postmenopause. The Penn Ovarian Aging Study (N=436) found a substantially increased risk of depressive episodes during this window, on the order of 2.5-fold, in women with no prior history of depression [17].

Musculoskeletal Pain

Joint stiffness and diffuse musculoskeletal pain are commonly reported by postmenopausal women. In the Women's Health Initiative, women randomized to estrogen-alone therapy reported significantly less joint pain than those on placebo, which is one of the pieces of evidence linking estrogen loss to joint symptoms [18].

When to Worry: Red Flags That Need Prompt Evaluation

Most postmenopausal symptoms are uncomfortable but not dangerous. Some presentations require urgent attention.

Postmenopausal Bleeding

Any vaginal bleeding that occurs after 12 months of amenorrhea is postmenopausal bleeding (PMB) until proven otherwise, and it should not be dismissed as normal spotting. PMB carries roughly a 5 to 10 percent risk of endometrial cancer. The American College of Obstetricians and Gynecologists (ACOG) recommends transvaginal ultrasound as the initial evaluation; an endometrial thickness of 4 mm or less has a high negative predictive value for endometrial cancer, though ultrasound findings still need to be interpreted alongside clinical risk factors [19].

Rapid Bone Loss

A repeat DEXA showing more than 3 to 5 percent bone density loss in a year warrants investigation for secondary causes: hyperparathyroidism, vitamin D deficiency, celiac disease, multiple myeloma, or medication effects (glucocorticoids, aromatase inhibitors).

New-Onset Cardiovascular Symptoms

Chest pain, exertional shortness of breath, or palpitations in a postmenopausal woman should prompt cardiovascular evaluation. Women present with atypical cardiac symptoms more often than men, which is part of why delayed diagnosis is a documented problem. The American Heart Association's 2020 scientific statement on the menopause transition and cardiovascular disease emphasized aggressively managing menopause-related risk factors such as hypertension, dyslipidemia, and metabolic syndrome (AHA statement) [20].

Treatment: Evidence-Based Options by Symptom

Treatment should be matched to the specific symptoms, their severity, and the individual's risk profile. There is no single protocol that fits every postmenopausal woman, and none of what follows is a substitute for an individualized prescribing decision with your own clinician.

Hormone Replacement Therapy (HRT)

HRT remains the most effective treatment for vasomotor symptoms and GSM. The 2022 NAMS position statement describes benefits generally outweighing risks for symptomatic women under age 60, or within 10 years of menopause onset, in the absence of contraindications [7]. Rather than a fixed rule for every patient, NAMS frames the decision around matching treatment intensity to a woman's individual risk profile and quality-of-life priorities, with periodic reassessment rather than an arbitrary stop date.

Systemic estrogen options: Oral conjugated equine estrogens, oral 17-beta estradiol, or transdermal estradiol patches. Transdermal delivery avoids first-pass hepatic metabolism and is associated with lower thrombotic risk than oral formulations. An observational study following postmenopausal women found transdermal estradiol was not associated with an increased risk of venous thromboembolism, while oral estrogen use was associated with a meaningfully higher risk; this kind of observational data cannot fully rule out confounding by indication, so individual risk assessment still matters [21].

Progestogen requirement: Women with an intact uterus need a progestogen (micronized progesterone or a synthetic progestin) alongside systemic estrogen to prevent endometrial hyperplasia. The PEPI trial (N=875) found that unopposed estrogen increased the rate of endometrial hyperplasia to roughly 62 percent at 36 months, which is the core evidence behind this requirement [22].

Duration: Current NAMS guidance favors periodic reassessment over an arbitrary time limit. Clinicians generally aim for the lowest effective dose with at least annual reassessment.

Non-Hormonal Systemic Options

For women who cannot or choose not to use HRT:

Fezolinetant (Veozah): An NK3 receptor antagonist approved by the FDA in May 2023 specifically for moderate-to-severe vasomotor symptoms. A randomized trial of fezolinetant reported that the 45 mg daily dose reduced moderate-to-severe hot flash frequency more than placebo over about 12 weeks.

SSRIs/SNRIs: Low-dose paroxetine (Brisdelle) is FDA-approved specifically for vasomotor symptoms. Venlafaxine and escitalopram are used off-label with moderate evidence of efficacy; off-label use should be discussed explicitly with your prescriber, including why it is being chosen over an approved option.

Gabapentin: Used off-label for hot flashes, typically dosed multiple times daily. A review of complementary and pharmacologic menopause therapies describes gabapentin as reducing hot flash frequency, though the size of the effect varies across the underlying trials and gabapentin causes sedation that limits its use for some women [24].

Local Vaginal Therapy for GSM

Low-dose vaginal estrogen (cream, vaginal ring, or vaginal insert formulations) is first-line for GSM specifically, as distinct from systemic vasomotor symptoms. Systemic absorption is minimal at these doses. ACOG guidance indicates that low-dose vaginal estrogen generally does not require a concurrent progestogen, even in women with a uterus, though this should still be confirmed with your own clinician given your history [25].

Ospemifene (Osphena): An oral selective estrogen receptor modulator (SERM) approved for pain with intercourse due to GSM. In a phase III trial (N=826), ospemifene significantly improved vaginal dryness and dyspareunia compared with placebo over 12 weeks [26].

Prasterone (Intrarosa): An intravaginal DHEA insert that converts locally to estrogen and testosterone, FDA-approved for moderate-to-severe dyspareunia related to menopause.

Bone Protection

Adequate calcium (from food and supplements combined) plus vitamin D form the foundation of bone protection; ask your clinician for a target specific to your labs and diet rather than assuming a fixed number applies. For women with osteoporosis or high fracture risk, pharmacotherapy options include oral bisphosphonates (alendronate, risedronate), denosumab, and, for very high fracture risk, romosozumab. In the FREEDOM trial (N=7,868), denosumab reduced vertebral fracture risk by 68 percent and hip fracture risk by 40 percent over 3 years compared with placebo [27].

Cardiovascular Risk Reduction

Postmenopausal dyslipidemia should be managed per ACC/AHA guidelines. Statin therapy is generally considered for women with an elevated calculated 10-year ASCVD risk, and blood pressure targets follow standard hypertension guidelines [10].

Building Your Follow-Up Schedule

A structured monitoring plan helps catch complications early and keeps treatment on track.

Year One After Confirmed Postmenopause

Complete the baseline lab panel described above. Start or adjust treatment based on results. If initiating HRT, a follow-up visit around 3 months out is typical, to assess symptom response, check blood pressure, and address side effects.

Annual Assessments

Repeat lipid panel, fasting glucose or HbA1c, and TSH on a periodic basis as your clinician recommends. Continue clinical breast exams and mammography per USPSTF recommendations. For women on HRT, reassess annually: symptom burden, bleeding patterns, blood pressure, and whether the risk-benefit balance still favors continuing.

Every 2 to 5 Years

Repeat DEXA scan roughly every 2 years if on osteoporosis therapy or if baseline T-score was in the osteopenic range. For women with a normal baseline DEXA, rescreening at 5-year intervals is often reasonable, though your clinician may adjust this based on your risk factors. Recheck 25-hydroxyvitamin D if supplementing or if initial levels were low.

The minimum lab follow-up for a postmenopausal woman not on HRT is generally: a lipid panel and fasting glucose periodically, TSH on a periodic basis, DEXA per the USPSTF schedule, and at least one clinical visit a year to reassess symptoms and screen for red flags like postmenopausal bleeding. This is a floor, not a substitute for a plan built around your own history with your clinician.